(Q34015309)

30 July 2017

Pharmacokinetic and technical comparison of Sandostatin® LAR® and other formulations of long-acting octreotide (English)

1 reference

30 July 2017

1 reference

Holger Petersen

1

1 reference

30 July 2017

Jean-Claude Bizec

series ordinal

2

1 reference

30 July 2017

Helmut Schuetz

series ordinal

3

1 reference

30 July 2017

Marie-Laure Delporte

series ordinal

4

1 reference

30 July 2017

9 September 2011

1 reference

30 July 2017

1 reference

30 July 2017

4

1 reference

30 July 2017

344

1 reference

Creative Commons Attribution 2.0 Generic

30 July 2017

start time

9 September 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1756-0500-4-344

0 references

cites work

From somatostatin to octreotide LAR: evolution of a somatostatin analogue

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3212992

Identification of chemically modified peptide from poly(D,L-lactide-co-glycolide) microspheres under in vitro release conditions

28 July 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3212992

Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects

28 July 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3212992

Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles

28 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-4-344

Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-4-344

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-4-344

PLGA-based drug delivery systems: importance of the type of drug and device geometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-4-344

The suitability of disintegrating force kinetics for studying the effect of manufacturing parameters on spironolactone tablet properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-4-344

Characterization of the initial burst release of a model peptide from poly(D,L-lactide-co-glycolide) microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-4-344

How porosity and size affect the drug release mechanisms from PLGA-based microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-4-344

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21906300

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21906300

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1756-0500-4-344

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference